Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News
March 4th 2025

FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

February 20th 2025

First Insulin Aspart Biosimilar Receives FDA Approval

February 18th 2025

Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

February 12th 2025

Biosimilar Insulin Linked to Lower Prices in Europe

January 31st 2025

FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

Video Series
View All
November 16th 2021

Evaluating Biosimilar Programs and Formularies

November 16th 2021

Integrating Biosimilars for HCPs, into Electronic Health Records, and in Clinical Pathways/Care Plans

November 9th 2021

Tracking Usage and Monitoring the Impact of Biosimilars

November 9th 2021

Protocols and Laws for Transitioning to Biosimilars

November 2nd 2021

Transitioning to a Biosimilar Program

November 2nd 2021

Increased Use of Biosimilars

October 26th 2021

Optimizing Transitions to Biosimilars

October 26th 2021

Optimizing Transitions to Biosimilars Continued

Video Interviews
View All
May 29th 2025

Cost Savings Potential Associated With the Use of Biosimilars

May 29th 2025

How the IRA is Reshaping Biosimilar Adoption

May 22nd 2025

The Road to Biosimilar Adoption: Navigating Interchangeability

May 22nd 2025

The Biosimilar Shift: How PBMs Are Reshaping Formularies

May 15th 2025

Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models

May 15th 2025

The Growing Market for Biosimilars

April 15th 2025

Biosimilar Adoption, Legislative Action With PBMs: JC Scott

March 4th 2025

A Pharmacist's Role in Selecting Effective, Affordable Breast Cancer Therapies

March 3rd 2025

The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

February 24th 2025

Assessing Patient Confidence With Biosimilars

Podcasts
View All
August 17th 2022

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

June 14th 2022

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

August 10th 2021

Exploring 2022 Trends in Health and Hospital Drug Spending With Vizient

July 17th 2019

Biosimilars Are Being Approved but Not Reaching the Market

January 9th 2019

Progress in the US With Biosimilars, but Opportunities Remain

October 27th 2018

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

March 10th 2018

Podcast: This Week in Managed Care—Verma on Health Data and Other Health News

January 24th 2018

The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange

January 13th 2018

Podcast: This Week in Managed Care—New Voluntary Payment Model and Other Health News

Continuing Medical Education
View All
May 30th 2025

New and Approved: FDA’s 2024 Drug Lineup

1.5 Credits / General Pharmacy
May 30th 2025

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

More News

2 experts in this video
February 24th 2025

Positioning Biosimilars in Clinical Practice

Ryan Haumschild, PharmD, MS, MBA, CPEL Casey Butrus, PharmD
Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous clinical validation, with providers increasingly integrating these alternatives by addressing knowledge barriers and demonstrating comparable therapeutic performance.
2 experts in this video
February 17th 2025

Key Structural and Operational Considerations for Biosimilar Adoption

Ryan Haumschild, PharmD, MS, MBA, CPEL Casey Butrus, PharmD
Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.
2 experts in this video
February 17th 2025

The Role of Private Label Agreements in Enhancing Access to Biosimilars

Ryan Haumschild, PharmD, MS, MBA, CPEL Casey Butrus, PharmD
Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.
2 experts in this video
February 10th 2025

Best Practices for Employers to Maximize Uptake of Biosimilars

Ryan Haumschild, PharmD, MS, MBA, CPEL Casey Butrus, PharmD
Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.
2 experts in this video
February 10th 2025

The Economic Impact of Biosimilars

Ryan Haumschild, PharmD, MS, MBA, CPEL Casey Butrus, PharmD
Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.
Kirollos Hanna, PharmD
January 29th 2025

Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.
France | Image Credit: lazyllama - stock.adobe.com
January 27th 2025

Ustekinumab Biosimilar Launches in France, Shifts the Autoimmune Disease Market

Cameron Santoro
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch.
Market share. | Image Credit: sirichai - stock.adobe.com
Published: January 23rd 2025 | Updated: January 23rd 2025

Biosimilar Market Share: Growth and Price Trends in Q1 2025

Cameron Santoro
Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine biosimilars have grown more slowly.
Patent litigation. | Image Credit: LALAKA - stock.adobe.com
January 22nd 2025

Patent Litigation Impacts on US Biosimilar Market Entry

Cameron Santoro
Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar market entry.
Pharmaceutical industry. | Image Credit: Africa Studio - stock.adobe.com
January 10th 2025

The Future of Pharmacy: Trends, Threats, Transformations

Cameron Santoro
The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future of drug access and affordability for patients across the nation.
The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.
December 28th 2024

Top 5 Biosimilar Articles of 2024

Cameron Santoro
The top 5 biosimilar articles touch on the growing biosimilar landscape, including recent FDA approvals, patent disputes, cost-saving potential, and challenges in market entry.
Paper with FDA approved on top of a magnifying glass and a keyboard | Image Credit: Pawel - stock.adobe.com
December 27th 2024

5 Key Drug Approvals and CRLs in 2024

Laura Joszt, MA
In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.
FDA approval with stamp. | Image Credit: Surendra - stock.adobe.com
December 20th 2024

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

Cameron Santoro
The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.
AJMC
December 16th 2024

Uptake of Rituximab Biosimilars in Medicare and Medicaid in 2019-2022

Jingjing Qian, PhD
Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US.
Seattle Washington skyline | Image Credit: © espiegle - stock.adobe.com
December 12th 2024

From Approval to Practice: Addressing the Hurdles in Biosimilar Integration

Skylar Jeremias
Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Health Policy. | Image Credit: Mohamad Zaki - stock.adobe.com
December 4th 2024

Policy Proposals Aim to Stimulate the Long-Term Sustainability of Infused Biosimilars

Cameron Santoro
Panelists proposed policy solutions to ensure long-term sustainability of infused biosimilars amid current challenges, including average sales price erosion and reimbursement issues.
FDA approval. | Image Credit: syahrir - stock.adobe.com
December 2nd 2024

FDA Approves Sixth Ustekinumab Biosimilar, Yesintek

Skylar Jeremias
The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease.
Patient access to medication. | Image Credit: Supatman - stock.adobe.com
November 22nd 2024

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

Cameron Santoro
Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.
Health care expenses. | Image Credit: izzuan - stock.adobe.com
November 20th 2024

Financial Incentives Drive Biosimilar Adoption in Japan

Cameron Santoro
Financial incentives provided to hospitals in Japan led to a significant increase in biosimilar oncology drug prescriptions.
James Chambers, PhD
November 13th 2024

Biosimilars Are Getting a Foothold and Becoming Preferred, Says Dr James Chambers

Laura Joszt, MA
Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.
FDA logo and website | Image credit: Postmodern Studio - stock.adobe.com
November 6th 2024

FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges

Skylar Jeremias
In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work to address drug shortages while emphasizing safety, efficacy, and public trust.
Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars
November 5th 2024

Removing Need for Switching Studies Could Change Payer Perspectives of Biosimilars

Laura Joszt, MA Peter Wehrwein
The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.
Retinal condition | Image Credit: Yakobchuk Olena - stock.adobe.com
October 30th 2024

Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD

Cameron Santoro
Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).
health policy chart | Image credit: JOURNEY STUDIO7 - stock.adobe.com
October 30th 2024

Exploring the Complexities of Biosimilars and Interchangeability

Skylar Jeremias
A panel of industry experts discussed the complexities of biosimilars and interchangeability, emphasizing the challenges in adoption, the need for regulatory and legislative solutions, and the importance of education to combat misinformation.
Cost of health care | Image Credit: Scott Hales - stock.adobe.com
October 28th 2024

Biosimilars Expand Access and Reduce Costs in Oncology, Immunology

Cameron Santoro
Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.
Market share increase | Image Credit: Kiattisak - stock.adobe.com
October 15th 2024

Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends

Cameron Santoro
Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.
FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com
October 11th 2024

FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

Skylar Jeremias
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Cost reduction in health care. | Image Credit: wladimir1804 - stock.adobe.com
October 7th 2024

Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

Cameron Santoro
Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.
Blue FDA approved stamp | Image credit: cartoon-stock - adobe.com
October 2nd 2024

Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

Laura Joszt, MA
Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.
Follitropin alfa | Image Credit: cristianstorto - stock.adobe.com
September 30th 2024

Biosimilar Follitropin Alfa Offers Fertility Savings in France

Cameron Santoro
A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system.
12345678
...
20>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo